Short answer
West Pharmaceutical Services (WST) filed an 8-K current report with the SEC on October 26, 2026 reporting Item 2.03 (Creation of a Direct Financial Obligation), Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement). $130.0 million outstanding under the 2019 Credit Agreement repaid in full on October 26, 2026.
West Pharmaceutical Services 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- $130.0 million outstanding under the 2019 Credit Agreement repaid in full on October 26, 2026
- Existing credit facility terminated after refinancing with proceeds from the New Credit Agreement
- No early termination penalties incurred, limiting refinancing-related costs
- Debt structure shifted to the New Credit Agreement, with terms and maturity detailed in Item 2.03
Item 2.03 · Creation of a Direct Financial Obligation
- New unsecured credit agreement: $750 million revolving facility plus $200 million term loan
- Five-year maturity, with term-loan amortization beginning March 31, 2028 and remaining balance due at maturity
- Proceeds available for working capital, capital expenditures, acquisitions, share repurchases and refinancing existing debt
- Interest margins tied to net leverage: 1.000%-1.500% for SOFR revolver borrowings and 1.125%-1.750% for SOFR term loans
- Net leverage covenant capped at 3.50x, or 4.00x during qualifying material acquisition periods
Other items in this filing:
- Item 1.01: Entry into a Material Definitive Agreement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other West Pharmaceutical Services 8-K filings
Get the next WST 8-K as it lands
Follow WST for push alerts, or ask the research agent what this filing means.